Lung Small Cell Carcinoma — Trials

Lung Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 381
Recruiting: 202
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (157)

clinicaltrialsPublishedShowing 101–103 of 103 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05199272	A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies	active not recruiting	Phase 1 / Phase 2	141	23andMe, Inc.INDUSTRY	2	Nov 15, 2024	clinicaltrials
NCT05566041	A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer(REPLATINUM)	active not recruiting	Phase 3	292	EpicentRx, Inc.INDUSTRY	1	Oct 31, 2024